MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bju.16117

Медицинская библиотека · BJU international · 2023

Personalised indocyanine-guided lymphadenectomy for prostate cancer: a randomised clinical trial.

de Pablos-Rodríguez Pedro, Claps Francesco, Rebez Giacomo, Vidal Crespo Natalia, Gómez-Ferrer Álvaro, Mascarós Juan Manuel, Collado Serra Argimiro, Caltrava Fons Ana, Rubio-Briones José, Casanova Ramon Borja Juan, Ramírez Backhaus Miguel

Рандомизированное исследованиеСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

To study the safety and efficacy of a personalised indocyanine-guided pelvic lymph node dissection (PLND) against extended PLND (ePLND) during radical prostatectomy (RP).

PATIENTS AND

METHODS

Patients who were candidates for RP and lymphadenectomy, with intermediate- or high-risk prostate cancer (PCa) according to the National Comprehensive Cancer Network guidelines, were enrolled in this randomised clinical trial. Randomisation was made 1:1 to indocyanine green (ICG)-PLND (only ICG-stained LNs) or ePLND (obturator fossa, external, internal, and common iliac and presacral LNs). The primary endpoint was the complication rate within 3 months after RP. Secondary endpoints included: rate of major complications (Clavien-Dindo Grade III-IV), time to drainage removal, length of stay, percentage of patients classified as pN1, number of LNs removed, number of metastatic LNs, rate of patients with undetectable prostate-specific antigen (PSA), biochemical recurrence (BCR)-free survival, and rate of patients with androgen-deprivation therapy at 24 months.

RESULTS

A total of 108 patients were included with a median follow-up of 16 months. In all, 54 were randomised to ICG-PLND and 54 to ePLND. The postoperative complication rate was higher in the ePLND (70%) vs the ICG-PLND group (32%) (P < 0.001). Differences between major complications in both groups were not statically significant (P = 0.7). The pN1 detection rate was higher in the ICG-PLND group (28%) vs the ePLND group (22%); however, this difference was not statistically significant (P = 0.7). The rate of undetectable PSA at 12 months was 83% in the ICG-PLND vs 76% in the ePLND group, which was not statistically significant. Additionally, there were no statistically significant differences in BCR-free survival between groups at the end of the analysis.

CONCLUSIONS

Personalised ICG-guided PLND is a promising technique to stage patients with intermediate- and high-risk PCa properly. It has shown a lower complication rate than ePLND with similar oncological outcomes at short-term follow-up.

Для цитирования: de Pablos-Rodríguez Pedro, Claps Francesco, Rebez Giacomo, Vidal Crespo Natalia, Gómez-Ferrer Álvaro, Mascarós Juan Manuel, Collado Serra Argimiro, Caltrava Fons Ana, Rubio-Briones José, Casanova Ramon Borja Juan, Ramírez Backhaus Miguel. Personalised indocyanine-guided lymphadenectomy for prostate cancer: a randomised clinical trial.. BJU international. 2023. DOI: 10.1111/bju.16117.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.